ランキング価格はじめての方へ
  1. 米国企業
  2. ABEONA THERAPEUTICS INC.
  3. Raw

ABEONA THERAPEUTICS INC.ABEO

時価総額
$2.5億
PER
細胞・遺伝子治療の臨床段階の新興企業。レト症候群などを対象とした遺伝子・細胞治療パイプラインを展開。2024年1月にAvenueと最大5,000万ドルの融資契約、2024年5月に7,500万ドルの株式公募実施。米国を中心に展開。
概要財務
サマリーテーブルに戻る
2011年
12月31日		2012年
12月31日		2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日		2024年
12月31日
Net loss-2,532,000-10,532,0004-26,778,000-14,526,000-21,873,000-27,319,000-56,671,000-76,282,000-84,234,000-84,936,000-40-54-64
Depreciation and amortization233,000419,0003,00011,000551,000825,000741,0002853322
Stock-based compensation expense1390,000439,00014-------57
Change in fair value of warrant and derivative liabilities------------11121
Accretion and interest on short-term investments-----------00-0
Amortization of right-of-use lease assets----------1111
Non-cash interest-------------2
(Gain) loss on disposal of property and equipment------------0-47,0002,000
Other receivables-----------02-1
Prepaid expenses and other current assets-31,000212,000-174,000-77,000287,000-160,00031-670,000-424,000-331,000-201
Other assets15,000-17,000-10,000-29,0004,000---3,000127,0007,000-00-0
Accounts payable and accrued expenses53,000567,000-1,176,00033,000-1,174,000-------522
Lease liabilities-------------1-1
Change in payable to licensor------------5--5
Other current liabilities-------------00
Net cash used in operating activities-7,609,000-3,955,0001,000----22,935,000-39,111,000-62,820,000-35,019,000-66-43-37-56
Capital expenditures40,00013,0002,000-308,000519,000860,0009614002
Proceeds from disposal of property and equipment----4------200
Purchases of short-term investments---------170207852157
Proceeds from maturities of short-term investments--------6688905352120
Net cash (used in) provided by investing activities-40,000-13,000-2,000----860,000-85,086,00060-83,714,00066-240-39
Proceeds from ATM sales of common stock, net of issuance costs6--127---17-8131415
Proceeds from sales of common stock under direct placement offering, net of issuance costs------------23-
Payments related to net settlement of restricted share awards-------------0-1
Proceeds from sales of common stock, net of issuance costs-------------70
Proceeds from issuance of long-term debt-------------20
Payment of debt issuance costs------------01
Net cash provided by financing activities3229,000---9251142254337104
Net increase in cash, cash equivalents and restricted cash--------118,720,000111-116,797,00025-2409
Derivative and warrant additions associated with loan and security agreement-------------1
Reclassification of derivative liability to equity-------------1
Changes in accrued property and equipment-------------0
Cash paid for interest------8,00011,000-----3
Cash paid for taxes-------------0